Quantum BioPharma Announces Private Placement to Strengthen Financial Position

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The offering, which received shareholder approval on September 26, 2025, is expected to be fully subscribed by entities controlled by company insiders Zeeshan Saeed and Anthony Durkacz. This strategic financing move represents a significant development for the biopharmaceutical company as it advances treatments for challenging neurodegenerative, metabolic, and alcohol misuse disorders.

The completion of this private placement will have substantial implications for the company's governance structure. Upon closing, the voting rights attached to the Class A shares will increase to 75.27%, effectively restoring them to nearly their original level when Quantum BioPharma went public in 2018. This concentration of voting power among key insiders provides stability in corporate decision-making while potentially raising questions about minority shareholder influence. The company has indicated that proceeds from the offering will be allocated toward general working capital requirements, supporting ongoing operations and development activities.

Quantum BioPharma's research and development efforts are primarily channeled through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which focuses on advancing the lead compound Lucid-MS. This patented new chemical entity has demonstrated potential in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The company maintains an active presence in the investment community, with regular updates available through its dedicated newsroom at https://ibn.fm/QNTM, providing stakeholders with ongoing transparency regarding corporate developments.

Beyond its core pharmaceutical research, Quantum BioPharma maintains strategic interests through its ownership position in Unbuzzd Wellness Inc., holding 20.11% of the company as of March 31, 2025. The relationship includes royalty arrangements that provide Quantum BioPharma with 7% of sales from the unbuzzd(TM) product until cumulative payments reach $250 million, after which the royalty decreases to 3% in perpetuity. This diversified revenue stream, combined with the company's portfolio of strategic investments managed through FSD Strategic Investments Inc., creates multiple pathways for financial sustainability as drug development programs progress through various clinical stages.